alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
EX-10.9





 Exhibit 10.9 

Copenhagen - August 2017 

Addendum to the Employment Contract 
  

 
 Galecto Biotech ApS 

CVR no. 34 87 83 66 
 Ole Maal0es Vej 3 

DK-2200 Copenhagen 
 (the
“Company’’) 
 and 
 Anders H. Pedersen 

*** 
 *** 

(the “Employee’’) 
 (each a “Party” and
jointly the “Parties”) 
 have today entered into this addendum (the “Addendum”) to the employment contract dated 23 January 2013
(the “Employment Contract”). 
  

	1.	 Termination 


  

	1.1	 The Parties agree that clause 16.1 of the Employment Contract shall lapse and that termination of the
employment shall be in accordance with clause 1.2 below. 


  

	1.2	 The Company may terminate the employment by 9 months’ notice. The Employee may terminate the employment by
3 months’ notice. The Parties must terminate the employment in writing with effect from the end of a month. 















	2.	 Other terms and conditions 



 

	2.1	 The Employee’s other terms and conditions of the employment according to the Employment Contract continue
unchanged. 


  

	2.2	 This Addendum shall be attached to the Employment Contract as an addendum. 



 

	3.	 Counterparts 


  


	3.1	 The Addendum is signed in duplicate, each Party retaining one counterpart. 



 

			
	Place: Copenhagen	  	Place: Copenhagen

  

			
	 Date: August 24, 2017
   For Galecto
Biote    pS
	  	Date: August 24, 2017

  

			
	 /s/ Hans Schambye
	  	 /s/ Anders H. Pedersen

	Hans Schambye	  	Anders H. Pedersen
```

[Congressional Record Volume 154, Number 179 (Wednesday, November 26, 2008)]
[Senate]
[Page S10781]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

              APPOINTMENT OF ACTING PRESIDENT PRO TEMPORE

  The PRESIDING OFFICER. The clerk will please read a communication to 
the Senate from the President pro tempore (Mr. Byrd).
  The legislative clerk read the following letter:
                                                      U.S. Senate,

                                        President pro tempore,

                                Washington, DC, November 26, 2008.
     To the Senate:
       Under the provisions of rule I, paragraph 3, of the 
     Standing Rules of the Senate, I hereby appoint the Honorable 
     Richard L. Durbin, a Senator from the State of Illinois, to 
     perform the duties of the Chair.
                                                   Robert C. Byrd,
                                            President pro tempore.

  Mr. DURBIN thereupon assumed the Chair as Acting President pro 
tempore.

                          ____________________
```
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

                    Notice is hereby given of a change in the meeting of the National Institute of Neurological Disorders and Stroke Special Emphasis Panel; R13 Review, November 21, 2024, 10:00 a.m. to November 22, 2024, 05:00 p.m., National Institutes of Health, Neuroscience Center, 6001 Executive Boulevard, Rockville, MD, 20852 which was published in the                     **Federal Register**                     on October 24, 2024, FR Doc. 2024-24884, 89 FR 85223.                

This notice is being amended to change the dates of this two-day meeting to December 2, 2024, and December 3, 2024. The meeting time remains the same. The meeting is closed to the public.

Dated: November 14, 2024.

David W. Freeman,

Supervisory Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2024-27045 Filed 11-19-24; 8:45 am]

BILLING CODE 4140-01-P
<TABLE> <S> <C>

<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
CONDENSED CONSOLIDATED BALANCE SHEET AND CONDENSED CONSOLIDATED STATEMENT OF
OPERATIONS FOUND ON PAGES 2 AND 3 OF THE COMPANY'S FORM 10-Q FOR THE
YEAR-TO-DATE AND IS QUALIFIED IN ITS ENTIRETY BY REFERENCE TO SUCH FINANCIAL
STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          DEC-31-1996
<PERIOD-START>                             JAN-01-1996
<PERIOD-END>                               SEP-29-1996
<CASH>                                          30,128
<SECURITIES>                                     8,110
<RECEIVABLES>                                   15,552
<ALLOWANCES>                                         0
<INVENTORY>                                     15,531
<CURRENT-ASSETS>                                70,454
<PP&E>                                           8,701
<DEPRECIATION>                                       0
<TOTAL-ASSETS>                                  83,705
<CURRENT-LIABILITIES>                           14,813
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        56,809
<OTHER-SE>                                      12,083
<TOTAL-LIABILITY-AND-EQUITY>                    83,705
<SALES>                                         59,251
<TOTAL-REVENUES>                                59,251
<CGS>                                           26,317
<TOTAL-COSTS>                                   26,317
<OTHER-EXPENSES>                                24,200
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                                   0
<INCOME-PRETAX>                                 10,281
<INCOME-TAX>                                     3,393
<INCOME-CONTINUING>                              6,888
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                     6,888
<EPS-PRIMARY>                                      .45
<EPS-DILUTED>                                      .45
        

</TABLE>
Exhibit 32.2
 
 CERTIFICATION PURSUANT TO
 18 U.S.C. SECTION 1350,
 AS ADOPTED PURSUANT TO
 SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
 
 
 In connection with the Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2011of Dutch Gold Resources, Inc., a Nevada corporation (the “Company”), as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Steve Keaveney, Chief Financial Officer of the Company certify, pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
 
 1. The Report fully complies with the requirements of Section 13(a) or15(d) of the Securities and Exchange Act of 1934, as amended; and
 
 2. The information contained in this Report fairly presents, in all material respects, the financial condition and results of operation of the Company.
 
 Date: May 13, 2011
 
 /s/Steve Keaveney
 Name: Steve Keaveney
 Title:  Chief Financial Officer
 (principal accounting officer)
<TABLE> <S> <C>

<ARTICLE>                                                        5
<MULTIPLIER>                                                 1,000
       
<S>                                                  <C>
<PERIOD-TYPE>                                                6-MOS
<FISCAL-YEAR-END>                                      JUN-28-1997
<PERIOD-START>                                         JUN-30-1996
<PERIOD-END>                                           DEC-28-1996
<CASH>                                                       6,774
<SECURITIES>                                                     0
<RECEIVABLES>                                              192,549
<ALLOWANCES>                                                     0
<INVENTORY>                                                101,129
<CURRENT-ASSETS>                                           313,758
<PP&E>                                                     131,407
<DEPRECIATION>                                                   0
<TOTAL-ASSETS>                                             551,849
<CURRENT-LIABILITIES>                                      113,510
<BONDS>                                                          0
<PREFERRED-MANDATORY>                                            0
<PREFERRED>                                                      0
<COMMON>                                                       222
<OTHER-SE>                                                 201,070
<TOTAL-LIABILITY-AND-EQUITY>                               551,849
<SALES>                                                    836,964
<TOTAL-REVENUES>                                           836,964
<CGS>                                                      692,390
<TOTAL-COSTS>                                              118,169
<OTHER-EXPENSES>                                             5,400
<LOSS-PROVISION>                                                 0
<INTEREST-EXPENSE>                                           7,827
<INCOME-PRETAX>                                             13,178
<INCOME-TAX>                                                 6,410
<INCOME-CONTINUING>                                          6,768
<DISCONTINUED>                                                   0
<EXTRAORDINARY>                                                  0
<CHANGES>                                                        0
<NET-INCOME>                                                 6,768
<EPS-PRIMARY>                                                0.320
<EPS-DILUTED>                                                0.320
        


</TABLE>
* Pursuant to 5 TH C IR . R. 47.5, the court has determined

that this opinion should not be published and is not precedent except under the limited circumstances set forth in 5 TH C IR . R. 47.5.4. IN THE UNITED STATES COURT OF APPEALS FOR THE FIFTH CIRCUIT

No. 98-50661 Conference Calendar

RICK THOMAS, Others Similarly Situated, Plaintiff-Appellant,

versus ALLAN B. POLUNSKY, Chairman, Texas Board of Criminal Justice, ET AL., Defendants-Appellees.

- - - - - - - - - - Appeal from the United States District Court for the Western District of Texas USDC No. EP-97-CV-286-DB

- - - - - - - - - - April 19, 1999 Before JONES, SMITH, and DUHÉ, Circuit Judges.
PER CURIAM: * Rick Thomas, Texas prisoner # 765101, appeals the district court’s grant of summary judgment for the defendants in this 42 U.S.C. § 1983 action. Thomas has not adequately briefed any argument relating to the district court’s grant of summary judgment. See Grant v. Cuellar , 59 F.3d 523, 524 (5th Cir. 1995); Brinkmann v. Dallas County Deputy Sheriff Abner , 813 F.2d 744, 748 (5th Cir. 1987).No. 98-50661 -2- Thomas’ appeal is without arguable merit and is frivolous. Accordingly, the appeal is DISMISSED. 5th Cir. R. 42.2. The dismissal of this appeal as frivolous counts as a strike for purposes of 28 U.S.C. § 1915(g). We caution Thomas that once he accumulates three strikes, he may not proceed in forma pauperis (IFP) in any civil action or appeal filed while he is incarcerated unless he is under imminent danger of serious physical injury. See 28 U.S.C. § 1915(g).
APPEAL DISMISSED; WARNING ISSUED.
```

[Federal Register Volume 89, Number 224 (Wednesday, November 20, 2024)]
[Notices]
[Pages 91774-91775]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-27047]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Institute of Neurological Disorders and Stroke; Notice 
of Closed Meeting.

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

[[Page 91775]]

    Name of Committee: National Institute of Neurological Disorders 
and Stroke Special Emphasis Panel; Clinical Trial Readiness Review 
Meeting.
    Date: December 13, 2024.
    Time: 10:00 a.m. to 3:00 p.m.
    Agenda: To review and evaluate grant applications.
    Address: National Institutes of Health, Neuroscience Center, 
6001 Executive Boulevard, Rockville, MD 20852.
    Meeting Format: Virtual Meeting.
    Contact Person: Ana Olariu, Ph.D., Scientific Review Officer, 
Scientific Review Branch, Division of Extramural Activities, NINDS/
NIH/DHHS, NSC, 6001 Executive Boulevard, Rockville, MD 20852, 301-
496-9223 [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.853, 
Clinical Research Related to Neurological Disorders; 93.854, 
Biological Basis Research in the Neurosciences, National Institutes 
of Health, HHS).

    Dated: November 14, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee 
Policy.
[FR Doc. 2024-27047 Filed 11-19-24; 8:45 am]
BILLING CODE 4140-01-P
```
## Reports & Submissions

Strategic Plans

Budget Submissions

Performance and Accountability Reports

Buy American Act Reports

Fair Act Reports

Miscellaneous
```

[Congressional Record Volume 154, Number 184 (Tuesday, December 9, 2008)]
[Senate]
[Page S10821]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

                              S E N A T E

Vol. 154

WASHINGTON, TUESDAY, DECEMBER 9, 2008

No. 184
```
Complete UAS LLC 11523 Palmbrush Trail Suite 353 Lakewood Ranch, FL 34202 December 29
, 2 0 1 5

U.S. Department of Transportation Docket Management System 1200 New Jersey Ave., SE Washington, DC 20590

Re: Request for Amendment to Exemption No. 13598 , Regulatory Docket No. FAA

– 2015

– 2795 under Section 333 of the FAA Reform Act and Part 11 of the Federal Aviation Regulations.

Dear Sir or Madam:
Pursuant to Section 333 of the FAA Modernization and Reform Act of 2012 (the “Reform Act”) and 14 C.F.R. Par t 11, Complete UAS LLC ( CUAS ), seeks to amend exemption No. 13598, Regu latory Docket No. FAA

– 2015

– 2795 ; Submitted by AeroUAVs for review June 8 2015 and subs equently granted by the FAA on November 16 , 2015.
The original exemption made a request to allow o perations of different Airframe models for:

 Aerial Photography and Videography for the real estate, construction, and utilities industries

 Agricultural Surveying and Application

 sUAS Operator Training

 Product Demonstrations

 Research and Development
There have been no changes in the request for exemption from specific regulations or conditions and reasons relative to public interest and safety that were the basis for granting the original exemption.
This letter requests the addition of additional Airframe models for commercial use in the aforementioned service operations. We are petitioning for exemption to enable AeroUAVs to operate additional UAS platforms that have been previously approved by exemp tion. The Requested UAVs are listed in Proprietary/Confidential Appendix A which is filed separately.

All those s UAS all weigh less than 55 lbs, have a built

- in capability to limit the height flown above the ground, to limit the radius of the distance it flies from the operator and to exclude it from Class B, C and D airspace including a no fly zone feature. Each system also has the failsafe function of the autopilot system, which means when the communication between the Main Controller and the transmitter is lost, the system will automatically trigger Return to Home and will land safely.
This submission does not include the Operating Manuals for models requested , as they have been reviewed by the Administrator in granting previous exemptions. Model specifi cs are listed in the AeroUAVs Operating Manual. Copies of all Operating Manuals for the individual models listed will be submitted on request.Complete UAS LLC 11523 Palmbrush Trail Suite 353 Lakewood Ranch, FL 34202

Accompanying this submission electronically via e

- mail are a cop ies of the Operations Manual and Appendix A submi tted to 333exemptions@faa.gov

.

Regards,

Timothy Ford President and CEO Complete UAS LLC 11523 Palmbrush Trail Suite 353 Lakewood Ranch, FL 34202 (314) 397

- 1110
```

[Federal Register Volume 89, Number 224 (Wednesday, November 20, 2024)]
[Notices]
[Page 91774]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-27046]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Center for Advancing Translational Sciences; Notice of 
Closed Meeting

    Pursuant to section 1009 of the Federal Advisory Committee Act, as 
amended, notice is hereby given of the following meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The grant applications and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the grant applications, the disclosure of which would 
constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Center for Advancing Translational 
Sciences Special Emphasis Panel; Tissue Chips in Space 2.0.
    Date: February 13-14, 2025.
    Time: 10:00 a.m. to 2:00 p.m.
    Agenda: To review and evaluate grant applications.
    Address: National Center for Advancing Translational Sciences, 
National Institutes of Health, 9609 Medical Center Drive, Bethesda, 
MD 20892 (Virtual).
    Contact Person: Alumit Ishai, Ph.D., Scientific Review Officer, 
Office of Grants Management and Scientific Review, National Center 
for Advancing Translational Sciences, National Institutes of Health, 
9609 Medical Center Drive, Suite 1E504, Bethesda, MD 20892, (301) 
827-5819, [email protected].

(Catalogue of Federal Domestic Assistance Program Nos. 93.859, 
Pharmacology, Physiology, and Biological Chemistry Research; 93.350, 
B--Cooperative Agreements; 93.859, Biomedical Research and Research 
Training, National Institutes of Health, HHS)

    Dated: November 14, 2024.
David W. Freeman,
Supervisory Program Analyst, Office of Federal Advisory Committee 
Policy.
[FR Doc. 2024-27046 Filed 11-19-24; 8:45 am]
BILLING CODE 4140-01-P
```
```

[Congressional Record Volume 155, Number 8 (Wednesday, January 14, 2009)]
[House]
[Page H303]
From the Congressional Record Online through the Government Publishing Office [www.gpo.gov]

  The SPEAKER pro tempore. Under a previous order of the House, the 
gentleman from Oregon (Mr. DeFazio) is recognized for 5 minutes.
  (Mr. DeFAZIO addressed the House. His remarks will appear hereafter 
in the Extensions of Remarks.)

                          ____________________
```
RELATED PARTY LOAN AGREEMENT


 


THIS AGREEMENT (this
"Agreement") is made and entered on June 5, 2018 by and between OFF Line Co., Ltd. (the "Lender") and OFF Line
Japan Co., Ltd. formerly known as OFF Line Hanbai Co., Ltd. (the “Company”).


 


IN CONSIDERATION OF
the Lender providing the Loan to the Company, and the Company repaying the loan to the Lender, both parties agree to keep, perform,
and fulfill the promises, conditions and agreements below:


 


1. Loan Amount and Interest


The Lender promises to loan
up to JPY50,000,000 ($460,000) USD to the Company (the "Loan") with unsecured, due on demand and non-interest bearing.


 


2. Payment


At any time while not in
default under this Agreement, the Company may pay the outstanding balance then owing under this Agreement to the Lender without
further bonus or penalty.


 


3. Governing Law


This Agreement will be construed
in accordance with and governed by the laws of Japan.


 


4. Amendments


This Agreement may only
be amended or modified by a written instrument executed by both the Company and the Lender.


 


5. Severability


The clauses and paragraphs
contained in this Agreement are intended to be read and construed independently of each other. If any part of this Agreement is
held to be invalid, this invalidity will not affect the operation of any other part of this Agreement.


 


6. General Provisions


Headings are inserted for
the convenience of the parties only and are not to be considered when interpreting this Agreement. Words in the singular mean and
include the plural and vice versa. Words in the masculine mean and include the feminine and vice versa.


 


7. Entire Agreement


This Agreement constitutes
the entire agreement between the parties and there are no further items or provisions, either oral or otherwise.


 


IN WITNESS WHEREOF, this Agreement has
been executed by each of the individual parties hereto on the date first above written.


 


Signed, sealed and delivered in the presence
of:


 


Lender: OFF Line Co., Ltd.


By: /s/ Koichi Ishizuka


President, CEO and Director


 


Company: OFF Line Japan Co., Ltd. fka OFF Line
Hanbai Co., Ltd.


By: /s/ Koichi Ishizuka


President, CEO and Director